IMBdx (461030) Fundamentals 2026 — Revenue Analysis | SniperIQ
IMBdx (461030) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩43.7B, trading at ₩3050.00 on the KOE. This SniperIQ fundamentals page covers IMBdx's valuation, profitability (net margin -150.1%), revenue (₩5.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is IMBdx's market cap?
IMBdx (461030) has a market capitalization of approximately ₩43.7B, trading at ₩3050.00 on the KOE. Market cap moves with the live share price.
What is IMBdx's P/E ratio?
IMBdx's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is IMBdx?
IMBdx runs a net profit margin of -150.1%, a gross margin of 23.4%, and an operating margin of -191.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does IMBdx generate?
IMBdx reported revenue of ₩5.3B for fiscal year 2025, with net income of -₩7.9B and earnings per share (EPS) of -565.99. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does IMBdx pay a dividend?
IMBdx does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is IMBdx financially healthy?
IMBdx carries a debt-to-equity ratio of 0.03x and a current ratio of 15.87x, with a market beta of 0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is IMBdx a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For IMBdx (461030) the key facts are: market cap ₩43.7B, revenue ₩5.3B, 52-week range 2905-12990. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track IMBdx's full fundamentals live
Get IMBdx's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.